177 related articles for article (PubMed ID: 2068476)
41. Aztreonam therapy for serious gram-negative infections in children.
Stutman HR; Chartrand SA; Tolentino T; Friedhoff L; Marks MI
Am J Dis Child; 1986 Nov; 140(11):1147-51. PubMed ID: 3766490
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of aztreonam in the treatment of serious gram-negative infections in a university hospital in Saudi Arabia.
Fayed DF; Dahmash NS; Saddique AA; Shibl AM
J Chemother; 1992 Jun; 4(3):167-70. PubMed ID: 1517810
[TBL] [Abstract][Full Text] [Related]
43. [Clinical efficacy of aztreonam in refractory infections in children].
Ogura H; Hamada F; Fujieda M; Matsumoto K; Araki K; Ogura Y; Kuramitsu M; Kurashige T; Kitamura I
Jpn J Antibiot; 1985 Nov; 38(11):3349-57. PubMed ID: 4094068
[TBL] [Abstract][Full Text] [Related]
44. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections.
Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR
Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056
[TBL] [Abstract][Full Text] [Related]
45. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
Hellinger WC; Brewer NS
Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
[TBL] [Abstract][Full Text] [Related]
46. Treatment of serious gram-negative infections with aztreonam.
Greenberg RN; Reilly PM; Luppen KL; McMillian R; Bollinger M; Wolk SM; Darji TB; Noorani AA
J Infect Dis; 1984 Nov; 150(5):623-30. PubMed ID: 6541672
[TBL] [Abstract][Full Text] [Related]
47. Aztreonam.
Clark P
Obstet Gynecol Clin North Am; 1992 Sep; 19(3):519-28. PubMed ID: 1436929
[TBL] [Abstract][Full Text] [Related]
48. Use of aztreonam in patients suffering from urinary tract infections with contraindications for the use of aminoglycosides.
Fraschini F; Scaglione F; Alessandria M; Gattei G
Chemioterapia; 1986 Oct; 5(5):319-21. PubMed ID: 3791478
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections.
Rodriguez JR; Ramirez-Ronda CH
Am J Med; 1985 Feb; 78(2A):42-3. PubMed ID: 4038578
[TBL] [Abstract][Full Text] [Related]
50. Aztreonam in the treatment of urinary tract infections: a multicenter trial.
Martelli A; Cortecchia V; Ventriglia L
Chemotherapy; 1989; 35 Suppl 1():8-14. PubMed ID: 2659294
[TBL] [Abstract][Full Text] [Related]
51. [Clinical evaluation of aztreonam (AZT) in the treatment of complicated urinary tract infections].
Mizutani S; Iwao N; Miyoshi S; Kameoka H; Yano H; Kishimoto T; Sakurai T; Wakatsuki A; Nakamura T; Honda M
Hinyokika Kiyo; 1989 Dec; 35(12):2155-61. PubMed ID: 2694836
[TBL] [Abstract][Full Text] [Related]
52. Randomized clinical trial of aztreonam and aminoglycoside antibiotics in the treatment of serious infections caused by gram-negative bacilli.
DeMaria A; Treadwell TL; Saunders CA; Porat R; McCabe WR
Antimicrob Agents Chemother; 1989 Aug; 33(8):1137-43. PubMed ID: 2679368
[TBL] [Abstract][Full Text] [Related]
53. Treatment of gram-negative infections with aztreonam.
Simons WJ; Lee TJ
Am J Med; 1985 Feb; 78(2A):27-30. PubMed ID: 4038577
[TBL] [Abstract][Full Text] [Related]
54. [Clinical study of aztreonam on respiratory tract infections caused by gram-negative pathogens].
Shimokata K; Totani Y; Morishita M; Hashigami H; Yamamoto M; Suetsugu S; Tanaka A; Umeda H; Sakai S; Kobayashi T
Jpn J Antibiot; 1985 Nov; 38(11):3415-33. PubMed ID: 3912526
[TBL] [Abstract][Full Text] [Related]
55. [Therapeutic effectiveness of aztreonam on severe infections associated with hematologic disorders. Hanshin Infection Study Group].
Hirayama F; Masaoka T; Shibata H; Nagai K; Kitani T; Horiuchi A; Kawagoe H; Yasunaga K; Okamoto Y; Yonezawa T
Jpn J Antibiot; 1985 Sep; 38(9):2402-12. PubMed ID: 4079014
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli.
Rodríguez JR; Ramírez-Ronda CH; Nevárez M
Antimicrob Agents Chemother; 1985 Feb; 27(2):246-51. PubMed ID: 4039118
[TBL] [Abstract][Full Text] [Related]
57. Aztreonam in gram-negative infections in children.
Sklavunu-Tsurutsoglu S; Gatzola-Karaveli M; Hitoglu-Makedu A; Paradelis AG; Tsurutsoglu G
Chemioterapia; 1987 Jun; 6(2 Suppl):415-7. PubMed ID: 3509461
[No Abstract] [Full Text] [Related]
58. Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections.
Naber KG; Dette GA; Kees F; Knothe H; Grobecker H
J Antimicrob Chemother; 1986 Apr; 17(4):517-27. PubMed ID: 3710959
[TBL] [Abstract][Full Text] [Related]
59. Overall clinical experience with aztreonam in the treatment of intraabdominal infections.
Henry SA
Rev Infect Dis; 1985; 7 Suppl 4():S729-33. PubMed ID: 3909331
[TBL] [Abstract][Full Text] [Related]
60. Role of aztreonam in lower respiratory tract infections.
Cook JL
Urology; 1988 Jun; 31(6 Suppl):33-6. PubMed ID: 3287748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
